Physician profile
Ana Martinez
NPI 1538701172
$1,405.84
in general payments reported to CMS, 2019-2025
23 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $39.62 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,405.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $222.76 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $180.16 | 2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $161.95 | 2025 | |
| Pfizer INC. | $144.46 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $114.07 | 2025 | Breztri, Airsupra |
| Intra-Sana Laboratories | $50.00 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Janssen Pharmaceuticals, INC | $49.45 | 2024-2025 | Spravato |
| Hologic Sales and Service, LLC | $48.71 | 2025 | Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.99 | 2025 | Jardiance |
| Amgen INC. | $43.72 | 2025 | Otezla, Repatha, Krystexxa |
| Aimmune Therapeutics, INC. | $40.53 | 2025 | Zenpep |
| Glaxosmithkline, LLC. | $37.24 | 2025 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $36.71 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $31.29 | 2025 | Zoryve |
| Lundbeck LLC | $28.57 | 2025 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.45 | 2025 | Caplyta |
| Vertex Pharmaceuticals Incorporated | $27.78 | 2025 | |
| Electromed, INC. | $23.35 | 2025 | Smartvest |
| Sanofi-Aventis U.S. LLC | $21.59 | 2025 | |
| Mayne Pharma Commercial LLC | $21.56 | 2025 | |
| Abbvie INC. | $20.80 | 2025 | |
| Merck Sharp & Dohme LLC | $14.38 | 2025 | Gardasil 9, Capvaxive |
| Lnhc, INC | $14.32 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.